Commentary
J. N. Benhammou et al. (University of California Los Angeles, and VA Greater Los Angeles Healthcare System, USA) aimed to determine whether diabetes and/or obesity are associated with adverse outcomes in direct-acting antiviral-treated HCV patients.
They conducted a retrospective study of 33,003 Veterans during a mean follow-up of 3 years. In this large Veterans cohort, pre-direct-acting antiviral diabetes increases mortality and liver-related events independent of sustained virologic response.
Continued vigilance is warranted in patients with diabetes despite sustained virologic response.
